RATIONALE: Drugs that interfere with cannabinoid CB1 transmission suppress food-motivated behaviors and may be useful as appetite suppressants, but there is uncertainty about the locus of action for the feeding-suppression effects of these drugs. OBJECTIVE: The present work was conducted to determine if two drugs that interfere with cannabinoid receptor transmission, AM251 and AM4113, have effects on food-reinforced behavior after administration into the lateral ventricle (intracerebroventricular (ICV)). RESULTS: Although systemic administration of both drugs can suppress food-reinforced behavior, neither AM251 (40, 80, and 160 microg) nor AM4113 (60, 120, and 240 microg) administered at various times prior to testing produced any suppression of food-reinforced operant responding on a fixed-ratio 5 schedule. Because the modulation of locomotion by drugs that act on CB1 receptors is hypothesized to be a forebrain effect, these drugs also were assessed for their ability to reverse the locomotor suppression produced by the CB1 agonist AM411. ICV administration of either AM251 or AM4113 reversed the locomotor suppression induced by the CB1 agonist AM411 in the same dose range that failed to produce any effects on feeding. CONCLUSIONS: This indicates that both AM4113 and AM251, when administered ICV, can interact with forebrain CB1 receptors and are efficacious on forebrain-mediated functions unrelated to feeding. These results suggest that CB1 neutral antagonists or inverse agonists may not be affecting food-reinforced behavior via interactions with forebrain CB1 receptors located in nucleus accumbens or hypothalamus and that lower brainstem or peripheral receptors may be involved.
RATIONALE: Drugs that interfere with cannabinoidCB1 transmission suppress food-motivated behaviors and may be useful as appetite suppressants, but there is uncertainty about the locus of action for the feeding-suppression effects of these drugs. OBJECTIVE: The present work was conducted to determine if two drugs that interfere with cannabinoid receptor transmission, AM251 and AM4113, have effects on food-reinforced behavior after administration into the lateral ventricle (intracerebroventricular (ICV)). RESULTS: Although systemic administration of both drugs can suppress food-reinforced behavior, neither AM251 (40, 80, and 160 microg) nor AM4113 (60, 120, and 240 microg) administered at various times prior to testing produced any suppression of food-reinforced operant responding on a fixed-ratio 5 schedule. Because the modulation of locomotion by drugs that act on CB1 receptors is hypothesized to be a forebrain effect, these drugs also were assessed for their ability to reverse the locomotor suppression produced by the CB1 agonist AM411. ICV administration of either AM251 or AM4113 reversed the locomotor suppression induced by the CB1 agonist AM411 in the same dose range that failed to produce any effects on feeding. CONCLUSIONS: This indicates that both AM4113 and AM251, when administered ICV, can interact with forebrain CB1 receptors and are efficacious on forebrain-mediated functions unrelated to feeding. These results suggest that CB1 neutral antagonists or inverse agonists may not be affecting food-reinforced behavior via interactions with forebrain CB1 receptors located in nucleus accumbens or hypothalamus and that lower brainstem or peripheral receptors may be involved.
Authors: Francisco Javier Pavon; Ainhoa Bilbao; Laura Hernández-Folgado; Andrea Cippitelli; Nadine Jagerovic; Gumersindo Abellán; M A Isabel Rodríguez-Franco; Antonia Serrano; Manuel Macias; Raquel Gómez; Miguel Navarro; Pilar Goya; Fernando Rodríguez de Fonseca Journal: Neuropharmacology Date: 2006-06-05 Impact factor: 5.250
Authors: Douglas Osei-Hyiaman; Michael DePetrillo; Pál Pacher; Jie Liu; Svetlana Radaeva; Sándor Bátkai; Judith Harvey-White; Ken Mackie; László Offertáler; Lei Wang; George Kunos Journal: J Clin Invest Date: 2005-05 Impact factor: 14.808
Authors: Galina Burdyga; Simon Lal; Andrea Varro; Rod Dimaline; David G Thompson; Graham J Dockray Journal: J Neurosci Date: 2004-03-17 Impact factor: 6.167
Authors: K S Sink; K N Segovia; L E Collins; E J Markus; V K Vemuri; A Makriyannis; J D Salamone Journal: Pharmacol Biochem Behav Date: 2010-03-27 Impact factor: 3.533
Authors: Robert B Laprairie; Abhijit R Kulkarni; Pushkar M Kulkarni; Dow P Hurst; Diane Lynch; Patricia H Reggio; David R Janero; Roger G Pertwee; Lesley A Stevenson; Melanie E M Kelly; Eileen M Denovan-Wright; Ganesh A Thakur Journal: ACS Chem Neurosci Date: 2016-04-25 Impact factor: 4.418
Authors: C L Limebeer; V K Vemuri; H Bedard; S T Lang; K P Ossenkopp; A Makriyannis; L A Parker Journal: Br J Pharmacol Date: 2010-09 Impact factor: 8.739
Authors: P A Randall; V K Vemuri; K N Segovia; E Ferreris Torres; S Hosmer; E J Nunes; J L Santerre; A Makriyannis; J D Salamone Journal: Pharmacol Biochem Behav Date: 2010-08-14 Impact factor: 3.533
Authors: Aliou B Gueye; Yaroslaw Pryslawsky; Jose M Trigo; Nafsika Poulia; Foteini Delis; Katerina Antoniou; Michael Loureiro; Steve R Laviolette; Kiran Vemuri; Alexandros Makriyannis; Bernard Le Foll Journal: Int J Neuropsychopharmacol Date: 2016-12-30 Impact factor: 5.176